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Poster Session-I 7358 consecutive children with high-risk lymphomas and solid tu-
mor malignancies were treated with cyclophosphamide and tar-
geted topotecan followed by autologous HSCT as consolidation
therapy in a phase I/II IRB-approved study between November
1998 and January 2004 at St. Jude. 21 participants (pts) were en-
rolled in the phase I portion of the study. 14 pts were enrolled in
phase I, level 1 consisting of topotecan 3mg/m2/day with subse-
quent doses targeted to total systemic exposure of 100 6 20 ng-
hr/ml (days -11 to -2) and cyclophosphamide 750mg/m2/day on
days -6 through -2 (total, 3.75g/m2). Topotecan concentrations
were measured on days -11 and -6 to determine subsequent dosage
adjustments. Cyclophosphamide dose escalation to 1g/m2/day (to-
tal, 5g/m2) on level 2 was excessively toxic, as 7 of 7 pts experienced
$ grade 3 regimen-related toxicity; 1 pt died of veno-occlusive dis-
ease. The next 37 pts were enrolled in phase II at level 1 as maxi-
mum tolerated dose was reached; further results will be on the 51
pts who received cyclophosphamide and topotecan at dose level 1.
Pts included neuroblastoma (26), sarcoma (8), lymphoma (8), brain
tumor (5), Wilms tumor (3), and retinoblastoma (1). Disease status
at enrollment included 11 (21.6%) CR1, 10 (19.7%) $CR2, 9
(17.6%) very good partial response, 7 (13.7%) partial response, 2
(3.9%) progressive disease, 10 (19.6%) stable disease, and 2
(3.9%) relapse disease. Median age at HSCT was 4.9 years (y)
(range, 1.5–21.3 y) and 52.9% were males. Of the 51 pts, 19 re-
ceived unmanipulated peripheral blood stem cell grafts and 32 mar-
row grafts. Most common grade 3 or 4 toxicities were hepatic,
gastrointestinal and skin. Pts achieved neutrophil and platelet en-
graftment at a median of 13 days (range, 8–33 days) and 24 days
(range, 8–91 days), respectively. Overall the median time to neutro-
phil engraftment for pts receiving marrow grafts was 18 days
(range, 10–33 days) and PBSC grafts 10 days (range, 8–12 days)
(p\ 0.0001). 25 (49%) remain alive at a median of 6.4 y (range,
4–9.8 y). 3- and 5-year OS and EFS for all and most common di-
agnoses are described in Table 1; none were statistically significant.
Cyclophosphamide 3.75g/m2 and targeted topotecan followed by
autologous HSCT produces acceptable toxicity and ability to
achieve long-term survival in children with high-risk lymphoma
and solid tumor malignancies; hepatic toxicity was dose-limiting
in the initial phase of the study.
The 3-year and 5-year OS and EFS for the 3 most common
diagnoses and all participants treated on this therapeutic
protocol.
3-year OS 3-year EFS 5-year OS 5-year EFSNeuroblastoma 73.1% 1/- 8.5% 42.3% 1/- 9.3% 57.7% 1/- 10.8% 38.5% 1/- 11.4%Lymphoma 75% 1/- 14.2% 50% 1/- 15.8% 75% 1/- 14.2% 50% 1/- 15.8%Sarcoma 50% 1/- 15.8% 37.5% 1/- 14.8% 50% 1/- 17.7% 37.5% 1/- 17.1%Total 64.7% 1/- 6.6% 41.2% 1/- 6.7% 56.7% 1/- 7.8% 39.2% 1/- 8.2%OS, overall survival; EFS, event-free survival198
PHOTO(CHEMO)THERAPY IN THE TREATMENT OF CUTANEOUS
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Steroid and immunosuppressant sparing treatments of cutaneous
chronic graft versus host disease (GVHD) in children are a desirable
strategy, due to serious side-effects especially on growing and devel-
oping children. Photo(chemo)therapy (PT) has been shown to exert
local immunomodulatory activity in a variety of diseases including
GVHD. Therefore, we investigated the effect of total 31 cycles of
PT (narrowband UVB, UVA-1, PUVA) in 28 pediatric patients
(pat.)with cutaneous cGVHD (10 lichenoid, 18 sclerodermoid). 25/
28 pat. (89%) presented with extensive GVHD and have been either
resistant to immunosuppressive therapy or showed contraindications
against standard immunosuppression. Underlying diseases for allo-
geneic stem cell transplantation were malignant and non malignant
diseases (18 and10, respectively) with a median follow up of 8,7 years(2.7–17.7). Stem cell source were bone marrow in 20/28 and periph-
eral blood in 8/28 pat. given after myeloablativ conditioning in 18 and
after reduced intensity conditioning in 10 pat. Topical therapy in all
pat. comprised corticosteroids and, in recent years pimecrolimus.
Treatment outcome after 10 UVA-1, 8 narrowband UVB, 7 oral
PUVA and 6 topical PUVA courses was evaluated retrospectively.1
pat. got narrowband-UVB monotherapy, 5 pat. received one and
21 pat. two and more systemic immunosuppressants in addition to
PT. PT was well tolerated by all pat. Improvement of skin lesions
was observed in all but one (96%) pat. Complete remission (CR)
was achieved in 7/31 (22%)courses, a very good partial response
(VGPR) that allowed tapering of immunosuppressive therapy and re-
sulted in CR in another 8 (25%). 8 courses (25%) induced a partial re-
sponse (PR) with subsequent tapering of immunosuppressants and
stable disease, 3 courses (9,6%) also led to PR but were followed by
relapse. 1 course was without effect (NR). One pat. did not respond
initially to narrowband UVB but completely cleared after being
switched to UVA-1 treatment.We conclude that PT is a feasible,
nonaggressive treatment that may be beneficial for pediatric patients
with cutaneous GVHD by reducing prolonged systemic immunosup-
pressive therapy. Further controlled prospective studies are required
to prove our expectations especially in UVA-1 as add on treatment for
sclerodermoid, extensive cutaneous GVHD in children.199
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Background: Pericardial effusion (PCE) has only sporadically
been reported in transplant recipients. We studied a large series of
pediatric patients undergoing unrelated umbilical cord blood trans-
plantation (UCBT) at a single center to investigate PCE comprehen-
sively.
Methods: Between 01/2000 and 05/2008, 423 consecutive pa-
tients (median age 4.3 years; range 0.1–20.2 years) undergoing
UCBT from a single cord blood unit (CBU) after myeloablative con-
ditioning regimen were studied (median follow-up 1.8 years; range,
0.5–8.7 years). By low resolution HLA-A and –B and high resolution
–DRB1 matching the CBU were 4/6 (53.8%), 5/6 (35.3%), or 6/6
(8.5%) matched. The patients (63% male; 33% CMV seropositive)
had malignant (53.2%; n5 225; leukemia, lymphoma, MDS, others)
and non-malignant (46.8%; n5 198; metabolic, immunodeficiency,
marrow failure; and hemoglobinopathies) diagnoses. Cytoreduction
contained TBI for 38.3% and cyclophosphamide for 69.5%
patients. The graft-vs.-host disease (GVHD) prophylaxis was
cyclosporine1cellcept in 25.8% (n 5 109) and cyclospori-
ne1methylprednisone in 73% (n 5 309) patients.
Results: A total of 108 (26%) patients developed at least one ep-
isode of PCE a median of 96 days (range, 9 – 2730 days) after trans-
plant. PCE severity was moderate to very large in 56 and very small
to moderate in 52 patients. Cardiac tamponade was seen in 28
(6.7%); pericardiocentesis was performed in 31 (7.3%); and 10
(2.4%) patients required pericardial window. Pericardial fluid did
not reveal infection by cytology, cultures, PCR, or other tests. Cu-
mulative incidence of PCE in patients with grades II-IV acute
GVHD was 35% compared to 22% in those with either grade I or
no evidence of acute GVHD. TBI, patient CMV serostatus, HLA
match, chronic GVHD, age or sex of the patient had no impact on
the incidence of PCE. PCE with tamponade was significantly higher
(p 5 0.02) and pericardiocentesis was needed more often (p 5 0.03)
in the patients on cellcept prophylaxis. The 1-yr post-UCBT
survival in patients developing PCE was 55% compared to 63% in
those without PCE. Twenty-eight (6.7%) patients with PCE had
concomitant pleural and/or peritoneal fluid collection consistent
with a ‘‘polyserositis syndrome’’.
Conclusion: Pericardial effusion occurs in a quarter of UCBT
recipients but only a few are clinically important. Large PCE
74 Poster Session-Irequiring drainage are more common with cellcept prophylaxis and
should be considered if there are post-transplant cardiorespiratory
problems.200
TWICE-DAILY INTRAVENOUS (IV) BUSULFAN (BU) X 4 DAYS IN CHIL-
DREN UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION (ALLOHSCT) IS PHARMACOKINETICALLY SIMILAR TO Q6
HOUR DOSING IN THE PEDIATRIC POPULATION
Waxman, I.1, Milone, M.C.2, Bhatia, M.1, Shaw, L.2, Moore, V.1,
Tallamy, B.1, Militano, O.1, Garvin, J.H.1, George, D.1,
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Busulfan (Bu) is often used as part of the conditioning regimen for
pediatric patients undergoing allogeneic (allo) stem cell transplanta-
tion (SCT). Current pediatric dosing recommendations are based on
age and weight, with children 4 years of age or younger receiving
a higher every 6 hour (q6h) dose (1 mg/kg/dose) than children older
than 4 (0.8 mg/kg/dose) (Wall et al, Blood, 2000a). Twice-daily
(q12h) dosing is an attractive alternative to q6h dosing, requiring
less nursing time and less accessing of the patient’s central venous
catheter. Twice-daily dosing is not currently in wide use, however,
as IV Bu has a narrow therapeutic range and there is no published
data confirming that q12h pharmacokinetics (PK) are comparable
to q6h PK. From April 2003 to November 2007, 42 pediatric pa-
tients (age # 21 yrs) with malignant (n 5 16) and nonmalignant (n
5 26) conditions underwent alloSCT (23 unrelated cord blood, 3 re-
lated cord blood, 8 matched unrelated donor peripheral blood or
marrow, 8 matched family donor peripheral blood or marrow)
with preparative regimens including IV Bu q12h x 8 doses (3.2mg/
kg/day, 4 mg/kg/day if age # 4 yrs) and subsequent IV Bu PK anal-
ysis. Patients received phenytoin/fosphenytoin seizure prophylaxis
and FK506/MMF GVHD prophylaxis. PK samples were obtained
at hr 1, 2, 3, 5, 6, 7 and 8 after start of 1st dose. Bu levels were mea-
sured by a GC-MS method on heparinized plasma. PK results were
compared to PK data from pediatric q6h dosing historical controls
derived from the literature (Booth et al, J Clin Pharmacol, 2007)
and from the database of the Toxicology Laboratory of the Hospital
of the University of Pennsylvania. IV Bu q12h clearance (Cl) and vol-
ume of distribution (Vd) point estimates (n 5 38) were similar to
published PK results for q6h dosing in the pediatric population
(q6 vs. q12h Cl [L/h]: 4.04 vs 4.46, respectively; q6 vs. q12h Vd
[L]: 12.8 vs. 13.3, respectively). There was no statistically significant
difference between the steady-state concentrations (Css) (n 5 35)
achieved with q12h dosing when compared to q6h patients well-
matched for age and weight (n5 90) in the University of Pennsylva-
nia database (7376 239 ng/mL vs. 6736 164 ng/mL, p5 0.25; q6h
vs. q12h, respectively). No patients developed VOD. This data sug-
gests that IV Bu q12h in children has a PK profile similar to q6h dos-
ing and is safe, while providing the benefits of reduced nursing time
and less accessing of the patient’s central venous catheter.201
INTRAVENOUS AND INTRATHECAL ENZYME REPLACEMENT BEFORE
AND AFTER HEMATOPOIETIC CELL TRANSPLANTATION FOR HURLER
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Hurler syndrome (HS; mucopolysaccharidosis type I) is a lyso-
somal storage disorder caused by a deficiency of iduronidase, with re-
sultant accumulation of glycosaminoglycans in viscera and brain.
Hematopoietic cell transplantation (HCT) has been shown to be
a life-saving measure for children with HS. To decrease the toxicity
of HCT we have offered intravenous iduronidase enzyme replace-
ment therapy (IV ERT) before and after HCT. Twelve children
with HS at a median age of 1.5 years at the time of myeloablativeHCT were eligible. Iduronidase (0.58 mg/kg/dose) was adminis-
tered intravenously in 11–14 weekly doses before HCT and 8 weekly
doses after HCT. The infusions were well tolerated. All patients de-
veloped antibodies to iduronidase, but on day 100 had.90% donor
hematopoiesis, suggesting that ERT prior to HCT is unlikely to al-
ter donor engraftment. All are alive and well, with a median follow-
up of more than 1 year after HCT. Patients with HS, however, also
develop central nervous system (CNS) pathology, and IV-adminis-
tered iduronidase has been shown ineffective in crossing the
blood-brain barrier. Encouraged by the results of intrathecal ERT
(IT ERT) studies in the animal model of HS, we reasoned that clin-
ical investigations incorporating IT ERT, IV ERT, and HCT may
provide increased benefit to HS patients. To date, we have enrolled
3 patients with HS on this IT ERT study. The dose administered is
0.05 mg/kg iduronidase in 3 mL of Elliot’s B solution. Four doses of
drug are administered: the first beginning at the time of IV ERT, the
second just prior to transplantation, the third 100 days post HCT,
and the last 180 days post transplantation. This timing was chosen
to deliver enzyme to the brain until it is anticipated that donor mi-
croglial cells are present in sufficient numbers to deliver enzyme to
the CNS. At present, one patient has received all doses, while the
others continue on study. The 2 patients who were transplanted
are alive and fully engrafted at day 100. Magnetic resonance imaging
and cerebrospinal fluid analysis at the time of IT ERT showed no ev-
idence of brain inflammation. Our data thus demonstrate that mul-
timodal cellular and enzyme therapy in HS is feasible. Importantly,
it affirms the safety of IT ERT, IV ERT, and HCT combination
therapy, and provides a rationale for application of this strategy to
additional HS patients in order to assess fully its impact on long-
term neuropsychological function of HS patients.202
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Hematopoetic stem cell transplantation (HSCT) is used success-
fully in children to treat a variety of disorders. Despite known clin-
ical risk factors, predicting which patients will develop major
complications remains difficult, and transplant-related mortality
approaches 20%. C-reactive protein (CRP) is an acute phase reac-
tant produced by hepatocytes in response to tissue damage, infec-
tion, and inflammation, and it has been shown to be a reliable
marker of systemic inflammation. Studies in adults have demon-
strated that elevated CRP may predict transplant complications,
specifically the development of acute graft-versus-host disease
(aGVHD) and non-relapse mortality (NRM). If similar findings
can be demonstrated in children, it may be possible to identify at-
risk patients who would benefit from more vigilant observation
during their transplant. We enrolled 70 patients (median age, 10
years; range: 3 months–20 years) undergoing allogeneic HSCT at
our institution, drew CRP levels at days 0 and 7, and analyzed
data based on the higher of these values for each patient. We
collected the following demographic information: age, gender,
disease, conditioning regimen and stem cell source. The develop-
ment of complications within 100 days, including severe infection
(defined as gram-negative bacteremia, fungal infections, or other
infections associated with hypotension/sepsis), aGVHD, hepatic
veno-occlusive disease, engraftment failure, relapse and NRM,
was recorded for each patient. Using the Wilcoxon rank sum test,
elevated CRP values were significantly associated with myeloabla-
tive versus reduced-intensity conditioning regimen (p 5 0.003),
malignant versus non-malignant disease (p 5 0.03), subsequent
significant infections (p 5 0.0005), and non-relapse mortality
(p 5 0.02). Conditioning regimen, infection, and non-relapse
mortality remained significant after multivariate analysis (p 5
0.002, p 5 0.0005, and p 5 0.03, respectively). On ROC analysis,
a CRP value .4.35 was 70% sensitive and 72% specific for
development of severe infection, and a CRP value of .7.05 was
72% sensitive and 78% specific for NRM. We did not find a
